Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;41(4):2431-2439.
doi: 10.3892/or.2019.7027. Epub 2019 Feb 21.

Upregulation and hypomethylation of lncRNA AFAP1‑AS1 predicts a poor prognosis and promotes the migration and invasion of cervical cancer

Affiliations

Upregulation and hypomethylation of lncRNA AFAP1‑AS1 predicts a poor prognosis and promotes the migration and invasion of cervical cancer

Hao Bo et al. Oncol Rep. 2019 Apr.

Abstract

Although lncRNA AFAP1 antisense RNA1 (AFAP1‑AS1) is considered an oncogenic lncRNA, little is known about the role of AFAP1‑AS1 in cervical cancer. In the present study, we found that AFAP1‑AS1 was elevated and hypomethylated in cervical cancer and was associated with a poor prognosis of patients with cervical cancer by analyzing the Cancer RNA‑Seq Nexus (CRN), MethCH and UCSC XENA databases. Subsequently, we knocked AFAP1‑AS1 expression down using siRNAs in cervical cancer cells. Wound healing experiments and matrigel invasion experiments revealed that the downregulation of AFAP1‑AS1 suppressed the migration and invasion of cervical cancer cells. Furthermore, western blot analysis demonstrated that the antitumor effects induced by the silencing of AFAP1‑AS1 were mainly mediated through the regulation of the Rho/Rac signaling pathway and epithelial‑mesenchymal transition (EMT)‑related genes. Taken together, the findings of the present study indicate that the expression level of AFAP1‑AS1 may be involved in the development of cervical cancer. Thus, AFAP1‑AS1 may be a novel prognostic biomarker and a potential therapeutic target for patients with cervical cancer.

PubMed Disclaimer

MeSH terms